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Abstract 
Background: Cellular biobanking is a key resource for collaborative networks planning to use same cells in stud-
ies aimed at solving a variety of biological and biomedical issues. This approach is of great importance in studies on 
β-thalassemia, since the recruitment of patients and collection of specimens can represent a crucial and often limiting 
factor in the experimental planning.
Methods: Erythroid precursor cells were obtained from 72 patients, mostly β-thalassemic, expanded and cryopre-
served. Expression of globin genes was analyzed by real time RT-qPCR. Hemoglobin production was studied by HPLC.
Results: In this paper we describe the production and validation of a Thal-Biobank constituted by expanded eryth-
roid precursor cells from β-thalassemia patients. The biobanked samples were validated for maintenance of their 
phenotype after (a) cell isolation from same patients during independent phlebotomies, (b) freezing step in different 
biobanked cryovials, (c) thawing step and analysis at different time points. Reproducibility was confirmed by shipping 
the frozen biobanked cells to different laboratories, where the cells were thawed, cultured and analyzed using the 
same standardized procedures. The biobanked cells were stratified on the basis of their baseline level of fetal hemo-
globin production and exposed to fetal hemoglobin inducers.
Conclusion: The use of biobanked cells allows stratification of the patients with respect to fetal hemoglobin produc-
tion and can be used for determining the response to the fetal hemoglobin inducer hydroxyurea and to gene therapy 
protocols with reproducible results.
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Background
Biobanking of biological materials, including viable cells, 
is a new and very relevant approach which involves a 
wide range of public and private institutions [1]. The 
number of biobanks is rapidly increasing worldwide, 
helping to create collaborative networks. The creation 
of these banks can tackle very important biomedical 
issues that require large numbers of tissue samples of the 
same groups of pathologies. In Europe, more than 225 
biobanks and institutions from over 30 countries that col-
lect samples and pathological/clinical data belong to the 
Biobanking and Biomolecular Resources Research Infra-
structure (BBMRI) [1]. Biobanking of biological material 
(cellular pellets, DNA, RNA) is important to organize 
collection of high-quality samples with reliable clinical 
information for diagnostics, therapy and research. On the 
other hand, highly informative experiments with biologi-
cal modifiers could be performed, at least in theory, only 
using validated biological material collected within cellu-
lar biobank [2, 3].
Cellular biobanking is a key step in a variety of 
“OMICS” analyses, as well as in the screening of bioac-
tive molecules for the development of novel therapeutic 
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protocols [4]. This is particularly important to test a vari-
ety of treatments on primary cells isolated from affected 
patients in order to develop novel diagnostic, prognostic 
and therapeutic approaches, toward personalized treat-
ments. The biological assay used to test therapeutic mol-
ecules on primary erythroid cells from β-thalassemia 
patients is based on one method called “two-phase cul-
ture procedure” developed by the Fibach’s research group 
[5, 6]. In this system, peripheral blood mononuclear cells 
(PBMCs) isolated from 20 to 25 ml of patients’ blood are 
seeded in a Phase I culture for about 7 days and then dif-
ferentiated into hemoglobin-producing erythroid cell for 
a further 7–10 day period (Phase II) by exposure to eryth-
ropoietin [5, 6]. This protocol has been widely applied to 
develop novel fetal hemoglobin (HbF) inducers [7, 8], 
to validate gene therapy strategies based on novel len-
tiviral vectors [9, 10] and to perform gene editing using 
approaches based on ZFN, TALEN, and CRISPR-CAS9 
[11–15].
A limitation of the two-phase culture and its use for 
biomedical approaches is the restricted yield of erythroid 
precursors cells (ErPCs) that can be obtained, because 
the two-phase culture cannot be proposed for parallel 
culturing of high number of ErPCs, in consideration of 
the need of blood sampling from patients, who undergo 
blood transfusion with different time frequency and 
scheduled time periods. With these considerations in 
mind, the generation of a cellular biobank that includes 
cellular expansion, freezing, cryopreservation, storage 
and, finally, subculturing after thawing, represents an 
innovative methodology to perform experiment in paral-
lel and without time constraint.
In this manuscript we describe (a) the generation of 
a cellular biobank (Thal-Biobank) from β-thalassemia 
patients; (b) its characterization with respect to main-
tenance of the phenotype (% of HbF production); (c) its 
validation, using frozen cryopreserved samples for thaw-
ing and subculturing in different laboratories and by test-
ing induction of HbF using hydroxyurea (HU). HU was 
chosen among the different available HbF inducers, since 
(a) it is already used in experimental therapy of patients 
affected by β-thalassemia and sickle-cell anemia and (b) it 
is the only drug approved by US Food and Drug Adminis-
tration for Sickle-cell disease (SCD) patients [16, 17].
Methods
Patients
Patients were recruited and blood samples obtained 
according to the Declaration of Helsinki and following 
specific approvals of the study by the Ethical Commit-
tees of Ferrara Hospital and Rovigo Hospital. The blood 
samples were collected from β-thalassemia patients after 
signature of the informed consent form.
Isolation and culture of peripheral blood cells (Protocol A)
Peripheral blood mononuclear cells (PBMCs) (from 
about 25  ml of blood) were collected in Vacutainer 
LH treated tubes (BD Vacutainers, Becton–Dickin-
son, UK). PBMCs isolation was obtained from whole 
blood by Ficoll-Hypaque density gradient centrifuga-
tion (Lympholyte®-H Cell Separation Media, Cedarlane, 
Euroclone, Italy). After the separation of the various 
blood components, the ring was harvested and washed 
once with 1× Dulbecco’s Phosphate Buffered Saline 
without Ca & Mg (DPBS W/O CA-MG, GIBCO, Invitro-
gen, Life Technologies, Carlsbad, CA, USA). CD34+ cells 
were selected from PBMCs using anti-CD34+ magnetic 
microbeads and magnetic activated cells sorting separa-
tion LS columns (both from Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s 
protocol. The separation in the column was done twice 
to increase the CD34+ cells purification. The obtained 
cells were maintained in culture with two different pro-
tocols. In the first protocol (Protocol A), the medium 
contained α-minimal essential medium (α-MEM, Sigma-
Genosys, Saint Louis, Missouri, USA), prepared from a 
powder and diluted with water; a solution of Penicillin-
Streptomycin (PEN-STREP 10,000  U/mL, Lonza, Ver-
viers, Belgium); 10  % fetal bovine serum (FBS, Celbio, 
Milan, Italy); 10 % conditioned medium (CM), obtained 
from cell cultures of bladder cancer cells (5637); 1 µg/ml 
of cyclosporin A (Sigma-Aldrich, Saint Louis, Missouri, 
USA), prepared from cyclosporine absolute ethanol and 
diluted in 1X DPBS (GIBCO, Invitrogen, Life Technolo-
gies Carlsbad, CA, USA), in the ratio 1:1. After 7  days 
in Phase I culture, the non adherent cells were washed 
once with 1X DPBS (GIBCO, Invitrogen, Life Technolo-
gies Carlsbad, CA, USA), and then cultured in Phase II 
medium. This medium contains α-MEM (Sigma Geno-
sys, Cambridge, UK), 30 % FBS (Celbio, Milan, Italy), 1 % 
deionized bovine serum albumin (BSA, Sigma Genosys, 
Cambridge, UK), 10−5 M β-mercaptoethanol (Sigma 
Genosys, Cambridge, UK), 2  mM  l-glutamine (Sigma 
Genosys, Cambridge, UK), 10−6 M dexamethasone 
(Sigma Genosys, Cambridge, UK), and 1  U/mL human 
recombinant erythropoietin (EPO Tebu-bio, Magenta, 
Milan, Italy), and stem cell factor (SCF, BioSource Inter-
national, Camarillo, CA, USA) at the final concentration 
of 10 ng/mL.
Isolation and culture of peripheral blood cells (Protocol C)
In the second protocol, named Protocol C, the isola-
tion of mononuclear cells was performed starting from 
20–25 ml of peripheral blood collected before transfusion 
from patients who gave informed consent. A mixture of 
Blood and PBS 1× at a 1:1.5 ratio was stratified on top of 
Lympholyte®-H Cell Separation Media. A monolayer of 
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PBMCs was obtained by centrifugation at 2000  rpm for 
30  min, at room temperature, and carefully transferred 
into new tube. PBMCs were washed twice in 50 ml PBS 
1×, and resuspended in 600 μl of BSA solution.
The isolation of CD34+ cells from PBMCs was per-
formed using the CD34+ MicroBead Kit, LS MiniMACS 
Column, by magnetic separation using an autoMACS 
Separator (all from Miltenyi Biotec). 100  μl of CD34+ 
MicroBead were added to the cell suspension and gen-
tly mixed for 15  min at 4  °C. Two washes were per-
formed before proceeding with column separation. Cells 
were resuspended in 1  mL of beading buffer (PBS1X, 
2mMEDTA, 0.5  %BSA) and loaded onto the column in 
two consecutive steps with beading buffer washes in 
between. To enrich for CD34+ cells, the eluted fraction 
was re-eluted into a second LS Column. Cells pellets 
were resuspended in 5 ml of growth medium.
Five ml of expansion medium contains: StemSpan 
Serum-Free Medium Expansion (Voden, Vancouver, 
Canada), 50  µl of StemSpan® CC100 Cytokine Cock-
tail for Expansion of Human Hematopoietic Cells Stem 
Cell Technologies (Voden, Vancouver, Canada), 2 U/mL 
erythropoietin (EPO, Tebu-bio, Magenta, Milan, Italy), 
10−6 M dexamethasone (Dexamethasone 21-phosphate 
disodium salt, Sigma-Aldrich, Saint Louis, Missouri, 
USA), 50  µl of a 100× Pennicilin/Streptomycin solu-
tion (Lonza, Verviers, Belgium). Cell growth and dif-
ferentiation was monitored over time. Fresh expansion 
medium was added to maintain cell confluence below 
5  ×  105  cells/mL. Cells were frozen between 7 and 
12 days of expansion.
Freezing, cryopreservation and thawing of peripheral 
blood cells isolated following Protocol C
Once the maximum in cell expansion was achieved, 
CD34+ cells were frozen in single vials of 5 ×  106 cells 
each, following a previously described method [18] using 
a solution made of: 40  % Iscove’s modified Dulbecco’s 
Medium (IMDM, Life Tecnologies, Carlsbad, CA, USA), 
50 % FBS (Celbio, Milan, Italy) and 10 % Dimethyl Sulfox-
ide RPE-ACS (DMSO, Carlo Erba, Italy).
Cells were thawed by immediate incubation at 37  °C 
and resuspended dropwise in Iscove Modified Dulbecco’s 
Medium (IMDM) with 5 % FBS. After a 10 min incuba-
tion at room temperature, the cell suspension was cen-
trifuged at 1200 rpm at room temperature for 5 min, the 
supernatant removed and the cells suspended in expan-
sion medium.
Characterization of CD34+ ErPC cultures 
by Fluorescence‑activated cell sorting (FACS) analysis
Phenotypic characterization of CD34+cells before and 
after cryopreservation, thawing and culturing in the 
presence of SCF and EPO was performed using FACS 
analyses using 200,000  cells and antibodies directed 
against the following markers: CD34, CD44, Glycophorin 
A (GPA), CD117, CD29. The ErPCs expansion has been 
analyzed by FACS using CD34 marker expression Allo-
phycocyanin (APC) cojugated and CD44 monoclonal 
antibody FITC-conjugated before thawing. Erythroid 
differentiation of the ErPC cultures was investigated 
studying GPA expression by FACS analysis using poly-
clonal anti-human Glycophorin A antibody/Rabbit/IgG 
conjugated (Thermo schientific, Pierce, Rockford, USA) 
and Rabbit IgG-heavy and light chain cross-adsorbed 
antibody R-Phycoerythrin (PE) conjugated (Bethyl, 
Temaricerche, Italy). The other employed antibodies were 
anti-CD117 monoclonal antibody PE-cojugated (Exalpha 
Bilogical Inc., USA); anti-CD29 monoclonal antibody 
FITC-conjugated (Thermo schientific, Pierce, Rockford, 
USA); anti-CD44 monoclonal antibody FITC-conjugated 
(Exalpha Bilogical Inc., USA).
For FACS analysis, one μl of anti-human GPA anti-
body was added to freshly isolated cells on ice in 100 μl 
1× PBS and 0.1  % fetal calf serum (FCS) for 30  min. 
Then, when appropriate, rabbit IgG-heavy and light 
chain cross-adsorbed R-PE conjugate antibody (Bethyl, 
Temaricerche, Italy) was added (1:50) to PBS-washed 
cells and a further incubation on ice (1× PBS, 0.1 % FBS) 
was carried out for 30 min; 20 μl of CD117 monoclonal 
antibody PE-conjugated, or both 10  μl of CD29 mono-
clonal antibody FITC-conjugated and CD44 monoclonal 
antibody FITC-conjugated were added to freshly isolated 
cells on ice in 100 μl 1× PBS and 0.1 % FCS for 30 min. 
Finally, cells were washed in 1× PBS and analyzed using 
the BD FACScan system (Becton, Dickinson & Company, 
Italy).
Benzidine staining
The benzidine assay was used to evaluate erythroid dif-
ferentiation. Five microlitres of 0.1 mM benzidine, resus-
pended in 2.86  % glacial acetic acid and activated with 
33 % H2O2, were added to the same volume of the cells. 
The percentage of resulting blue cells indicates the level 
of erythroid differentiation.
Treatment with hydroxyurea
About 4  days after thawing the CD34+ cells have been 
treated with hydroxyurea using a concentration previ-
ously tested on erythroleukemic K562 cells. We used 
2–3 × 106 cells for RNA extraction to T0. Then, the cells 
were washed twice with 1× DPBS (GIBCO, Invitrogen, 
Life Technologies Carlsbad, CA, USA). From the pellet 
obtained we have done hemoglobins analysis by HPLC 
(high performance liquid chromatography) and tran-
script analysis by RNA extraction.
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RT‑PCR and qPCR analysis
The total cellular RNA was extracted by TRI Rea-
gent® (Sigma-Aldrich, Saint Louis, Missouri, USA). 
The isolated RNA was washed once with cold 75  % 
ethanol, dried and dissolved in diethylpyrocar-
bonate-treated Water Molecular Biology Reagent 
(WMBR, nuclease free, Sigma-Aldrich, Saint Louis, 
Missouri, USA) before use. For gene expression 
analysis 1  μg of total RNA was reverse transcribed 
by using the TaqMan® Reverse Transcription Rea-
gents and random hexamers (Applied Biosystems, 
Life Technologies, Carlsbad, CA, USA). Quantita-
tive real time PCR assay, to quantify the expression 
of the globin genes, was carried out using gene-spe-
cific double-quenched probes. Probes are labeled 
in 5′ with different fluorochromes, whereas in 3′ 
the BHQ (Black Hole Quencher™) is present. Reac-
tion mixture contained 1× iQTM Multiplex Power-
mix (Bio-Rad, Hercules, California, USA), 300  nM 
forward and reverse primers and the 200 nM probe. 
The assays were carried out in iCycler IQ5 (Bio-Rad, 
Hercules, CA, USA). After an initial denaturation at 
95  °C for 30  s, the reactions were performed for 50 
cycles (95  °C for 10  s, 60  °C for 45  s). To compare 
gene expression of each template amplified was used 
ΔΔCt method employing software IQ5 (Bio-Rad, 
Hercules, California, USA).
High performance liquid chromatography (HPLC)
ErPCs were harvested, washed once with PBS and the 
pellets were lysed. After incubation on ice for 15 min, and 
spinning for 5  min at 14,000  rpm in a microcentrifuge, 
the supernatant was collected and injected. Hb proteins 
present in the lysates were separated by cation-exchange 
HPLC [19], using a Beckman Coulter instrument System 
Gold 126 Solvent Module-166 Detector. Hemoglobins 
were separated using a PolyLC (Columbia, MD, USA) 
PolyCAT-A model (35 mm × 4.6 mm) column; samples 
were eluted in a solvent gradient using aqueous sodium 
chloride-BisTris-KCN buffers and detection was per-
formed at 415 nm. The standard controls were the puri-
fied HbA (SIGMA, St Louis, MO, USA) and HbF (Alpha 
Wassermann, Milano, Italy).
Genomic DNA extraction
The DNA was extracted from 200–300 μL of whole blood 
using QiAmp DNA Mini Kit & QiAmp DNA Blood Mini 
Kit (QIAGEN, Hilden, Germany) according to manufac-
ture’s protocol. The DNA obtained was visualized on a 
UV transilluminator after 0.8  % agarose gel electropho-
resis and quantified using the spectrophotometer Smart-
Spec ™ Plus (Biorad Smartspec Plus, Bio-Rad, Hercules, 
California, USA).
Polymerase chain reaction (PCR) and sequencing reactionΒ-globin gene was amplified starting from 300  ng of 
genomic DNA. Each reaction was carried out in a final 
volume of 100 μL, in the presence of 1× buffer (10 mM 
Tris–HCl pH 8.8, 1.5  mM MgCl2, 50  mM KCl, 0.1  % 
Triton X-100), 33  μM dNTPs, 0.25  μM forward and 
reverse primers, 2  U of DyNAzyme™ II DNA Polymer-
ase (Finnzymes, Espoo, Finland) or DNA polymerase 
DreamTaq™ 5  U/µl (MBI Fermentas, Burlington, ON, 
Canada) and ultra-pure water. Each reaction was sub-
jected to an initial denaturation step of 2  min at 94  °C. 
The 35 PCR cycles used were as follows: denaturation, 
30 s at 94 °C; annealing, 30 s at 65 °C; elongation, 1 min 
at 72  °C. PCR products were analyzed by agarose-gel 
electrophoresis to 1 % before being purified for sequenc-
ing. The PCR products were displayed on a UV transil-
luminator after 1 % agarose gel electrophoresis. The PCR 
products were purified with MicroClean (Microzones 
Limited, Haywards Heath, West Sussex, UK) and were 
sequenced in both directions using the PCR primers 
forward and reverse and the BigDye® Terminator ver-
sion 1.1 Cycle Sequencing Kit (Life Technologies, Carls-
bad, CA, USA). The reaction products were purified 
from unincorporated ddNTPs by using a 96-well Multi-
Screen™ (Merck Millipore KGaA, Darmstadt, Germany) 
plate containing Sephadex™ G-50 Superfine (Amersham 
Biosciences, UK). Sequencing was performed by BMR 
Genomics (Padua, Italy), while the obtained sequence 
data were analyzed by the Sequence Scanner, version 1.0 
(Applied Biosystems, Life Tecnologies, Carlsbad, CA, 
USA) software.
Synthetic oligonucleotides
The oligonucleotides used as primers in PCR and 
sequencing reactions were synthesized by Sigma Geno-
sys (Cambridge, UK) and reported in Table  1. The RT-
qPCR (reverse transcription quantitative polymerase 
chain reaction) primers and probes were purchased from 
Applied Biosystems (Life Technologies, Carlsbad, CA, 
USA) and reported in Table  2. All the oligonucleotides 
were designed using the software Primer Express™, ver-
sion 2.2 (Perkin-Elmer, Applied Biosystems, Life Tech-
nologies, Carlsbad, CA, USA).
Results
Production of the cellular Thal‑Biobank
The cellular Thal-Biobank is composed of 779 biobanked 
specimens from 8 healthy donors and 72 patients with 
sickle cell anemia (SCA) and β-thalassemia. The complete 
list of biobanked cells and vials is reported in Additional 
file 1: Table S1, which includes for all the patients the gen-
otype, the XmnI (rs7482144 ±), two BCL11A (rs1427407 
G/T, rs10189857 A/G) and one MYB (rs9399137 C/T) 
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polymorphisms. A summary of the composition of the 
cellular Thal-Biobank is reported in Fig. 1, which shows 
the distribution of the genotypes (1A and B) and related 
polymorphisms that are associated with modulation of 
HbF expression (1C). The most frequent genotypes are 
β039/β039 (29 patients), β+IVSI-110/β039 (17 patients) 
and β+IVSI-110/β+IVSI-110 (8 patients).
Kinetics of erythropoietin (EPO)‑induced hemoglobin 
production following subculturing of cryopreserved ErPCs 
from β‑thalassemia patients
We cryopreserved only cells exceeding 90 % positivity for 
CD34 marker, starting from 7–8 days of expansion. Fig-
ure 2a shows a representative experiment indicating the 
proportion of CD34+ cells after 2, 4 and 8 days of phase 
I culture. As expected, at this stage cells do not express 
marker of erythroid differentiation (CD235a, or GPA) 
and still express high levels of CD44, an adhesion mol-
ecule that is reduced with erythroid progression (Fig. 2b). 
Quantitative data are shown in panel C of Fig.  2, while 
the cell growth potential from day 4 to day 8 of subcul-
turing of the cryopreserved cells is shown in Fig. 2d.
We characterized the cell phenotype over time by flow 
cytometry using a panel of antibodies recognizing “early” 
erythroid progenitor/adhesion markers (CD117, CD44, 
CD29) as well as a “late” erythroid marker (GPA) (Fig. 3). 
As erythroid maturation progresses a down regulation of 
CD117, CD44 and CD29 is observed (Fig. 3a–d, f–h) and 
concurrently an upregulation of GPA expression (Fig. 3a, 
e, i). Data obtained using CD71 (transferrin receptor 
1) confirm that, as expected, this erythroid associated 
marker is present in nearly 100  % of the EPO-cultured 
ErPCs since day 4 of culture (not shown). Interestingly, 
the decrease of BFUe associated markers (i.e. CD44) and 
the increase of CFUe associated markers (i.e. GPA) are 
compatible with the BFUe → CFUe switch found in cul-
tured erythroid progenitors by several research groups. 
This phenotypic characterization is very similar to that 
reported by Chen et al. [20], Li et al. [21] and Mori et al. 
[22].
Remarkably, the majority of the cryopreserved sam-
ples (more than 90  %) exhibit low proportion of benzi-
dine-positive (hemoglobin containing) cells (Fig.  4a). In 
fact, the proportion of benzidine-positive cells at T0 was 
always less than 8–15 % in thawed samples. The progres-
sive increase in the proportion of benzidine-positive 
cells at 4 and 9 days of subculturing in Phase II medium 
(Fig.  4a), confirms erythroid maturation measured by 
GPA staining.
Beside phenotypic characterizations of the cells (Figs. 2, 
3, 4a), we were interested in determining whether this 
approach allows stratification of the patients with respect 
to HbF production. The level of HbF synthesis can greatly 
vary between patients’ ErPCs (Fig.  4b, c). When com-
paring baseline levels of HbF synthesis across samples, 
there is a good correlation between the HbF levels found 
in ErPCs induced following the classical two-phases dif-
ferentiation protocols developed by the Fibach’s group 
and cryopreserved samples from same β-thalassemia 
patients, as shown in Fig. 4d.
Biobanked cells originated from different blood sampling 
of a same β‑thalassemia patient maintain the same 
hemoglobin pattern
The first validation of the cellular Thal-Biobank was 
undertaken following careful analysis of the hemoglobin 
pattern produced by cryopreserved samples developed 
using blood sampling from a same patients performed 
at different periods of time. The HPLC analysis of the 
Table 1 Primers used in  the polymerase chain reactions 
and in the sequencing reactions for β-globin gene
For each primer the nucleotide sequence and melting temperature (Tm) have 
been reported
Primer Sequence (5′–3′) Tm (°C)
Forward primer BGF 5′-GTGCCAGAAGAGCCAAGGACAGG-3′ 72.1
Forward primer T12F 5′-AGACCTCACCCTGTGGAGCC-3′ 67.9
Forward primer T3F 5′-ACAATCCAGCTACCATTCTGCTTT-3′ 65.7
Forward primer BG6F 5′-CGCTTTCTTGCTGTCCAATTTC-3′ 66.7
Forward primer BG5SF 5′-GCCTGGCTCACCTGGACA-3′ 66.7
Reverse primer BG4 5′-TCAGGAGTGGACAGATCCCC-3′ 66.5
Reverse primer T12R 5′-AGTTCTCAGGATCCACGTGCA-3′ 67.1
Reverse primer BGR 5′-CACTGACCTCCCACATTCCCTTTT-3′ 69.8
Reverse primer BGi2R 5-‘GTTGCCCAGGAGCTGTGG-3′ 67.1
Table 2 Primers and  probes employed in  the multiplex 
quantitative real-time PCR
The 5′ and 3′ chromogenic molecules are underlined in the sequence
Primer Sequence
Forward primer α-globin 5′-CGACAAGACCAACGTCAAGG-3′
Reverse primer α-globin 5′-GGTCTTGGTGGTGGGGAAG-3′
α-globin probe 5′-HEX-ACATCCTCTCCAGGGCCTCCG-BHQ-3′
Forward primer β-globin 5′-GGGCACCTTTGCCACAC-3′
Reverse primer β-globin 5′-GGTGAATTCTTTGCCAAAGTGAT-3′
β-globin probe 5′-Texas Red-ACGTTGCCCAGGAGCCTGAAG-
BHQ-3′
Forward primer γ-globin 5′-TGACAAGCTGCATGTGGATC-3′
Reverse primer γ-globin 5′-TTCTTTGCCGAAATGGATTGC-3′
γ-globin probe 5′-FAM-TCACCAGCACATTTCCCAGGAGC-
BHQ-3′
Forward primer RPL13A 5′-GGCAATTTCTACAGAAACAAGTTG-3′
Reverse primer RPL13A 5′-GTTTTGTGGGGCAGCATACC-3′
RPL13A probe 5′-CY5-CGCACGGTCCGCCAGAAGAT-BHQ-3′
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hemoglobin produced by cryopreserved and subcul-
tured ErPCs isolated on March 2013 and November 2013 
from a same patient shows that the hemoglobin pattern 
is stable (Fig. 5a, b). HPLC analyses on hemolysates from 
three different patients’s ErPCs corroborate this finding. 
Importantly, ErPCs derived from blood drawn from the 
same patient at different times maintain an almost iden-
tical pattern of hemoglobin production, indicating that 
this approach allows reproducible yield in Hb synthesis 
(Fig. 5c–e).
Biobanked samples of a same β‑thalassemia patient frozen 
and subcultured at different time periods maintain the 
same hemoglobin pattern
An important validation of the biobanked samples is 
to show that Hbs types and proportions do not change 
in cryopreserved samples of the same individual when 
independently thawed and sub cultured at different time 
and throughout differentiation. This was confirmed as 
shown in a representative experiment in Fig.  5f, g. The 
proportion of HbF and HbA production does not sig-
nificantly change when vials of same patients are taken 
from the Thal-Biobank and the cells are thawed and 
differentiated in  vitro. Along with monitoring CD117, 
CD44, CD29 and GPA antigens expression, we analyzed 
by HPLC the Hb pattern after 4 and 8  days in cellular 
cultures from 14 patients exhibiting low or high endog-
enous levels of HbF production. A summary of the 
data is reported in Fig. 6 and all the data in Additional 
file  2: Table  S2, which clearly show a good reproduc-
ibility in production of the different hemoglobins, with 
few exceptions (i.e. AVLTF, AVLT23, Fe27 and Fe57, see 
Additional file 2: Table S2).
Biobanked samples thawed and subcultured in different 
laboratories maintain similar patterns of hemoglobin 
production
We next determined whether biobanked samples deliv-
ered frozen to different laboratories, thawed, subcultured 
and analyzed for hemoglobin content maintain the same 
phenotype. The results of this set of experiments are 
shown in Fig. 7 and formally demonstrate that the hemo-
globin pattern is fairly reproduced in different laborato-
ries (in the case reported at the Biotechnology Center 
of Ferrara University and at the Weill Medical College 
of Cornell University, NY). A significant correlation 
Fig. 1 a Distribution of genotypes among consented patients affected by β-thalassemia and sickle-cell anemia (SCA) within the cellular Thal-
Biobank. b Number of patients, related genotype and number of vials cryopreserved. c Distribution (expressed as percentage) of the XmnI 
(rs7482144 −/+), BCL11A (rs1427407 G/T, rs10189857 A/G) and MYB (rs9399137 C/T) polymorphisms
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Fig. 2 a Expression CD34 cell surface marker (FITC- or APC-conjugated antibody) in erythroid progenitor cells throughout expansion phase (Phase 
I) in Protocol C. b Expression of CD235a (GPA) and CD44 at day 8 of the expansion phase. Samples labeled with CD34-44-235a antibodies are repre-
sented in blue over IgG controls, in red. c Proportion of CD34-positive cells during the expansion time. Data represent the average ±SD from three 
independent expansion experiments. d Changes in cell number/ml from day 4 to day 8 after the thawing procedure. Data represent the average 
±SD using four cryopreserved vials obtained from 4 different β-thalassemia patients
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Fig. 3 a Representative experiment showing the variation of expression of the hematopoietic stem cell marker CD117, adhesion molecule marker 
CD44, beta1-integrin surface marker CD29, and erythroid differentiation marker CD235 (GPA) in undifferentiated cells (day 0) and in cells at two 
progressive stages of erythroid maturation (day 4 and 8). b–i Quantitative data showing the % of cells expressing the indicated markers (b–e) and 
the mean fluorescence values (MF) (f–i) after FACS analyses using antibodies recognizing CD117 (b, f), CD44 (c, g), CD29 (d, h) and GPA (e, i). The 
data represent the average ±SD obtained in seven independent experiments using vials obtained from 7 different β-thalassemia patients
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was found for both HbF (Fig.  7a) and HbA (Fig.  7b) 
productions.
Final validation: induction of fetal hemoglobin (HbF) using 
biobanked samples
To assess the versatility of this system in HbF induction 
studies, we induced specimens with HU and isolated 
their RNA content. On these we performed RT-qPCR 
analysis (in order to quantify the fold induction of 
γ-globin mRNA) while cytoplasmic extract were used 
for HPLC analysis (in order to quantify the induction 
of HbF). The analysis was performed using ErPCs from 
groups of β0- and β+-thalassemia patients. The major-
ity of β0-thalassemia patients were homozygous β0-39/
β0-39 (29/65), while the majority of the β+-thalassemia 
patients were characterized by a β+-IVSI-110 genotype 
(8/65 homozygous and 20/65 heterozygous, see Fig.  1). 
In addition we analyzed specimens from 7 patients with 
compound βS/β thal or homozygote βS/S SCA. The 
results obtained using protocol C were compared with 
the results obtained using the two-phase protocol devel-
oped by the Fibach’s group. In evaluating HbF varia-
tions we used the algorithm: % of HbF increase = (%HbF 
induced cells  −  %HbF uninduced cells)/(100  −  %HbF 
uninduced cells) × 100. This algorithm accounts for dif-
ferent proportion of HbF in different samples at steady 
state in our culture conditions (see Fig. 4). Following this 
algorithm, induction of HbF was quantified in biobanked 
samples induced with HU using protocol C. The distribu-
tion of HbF induction was similar to that obtained using 
the two-phases protocol. The results on fold increase of 
γ-globin mRNA in HU treated cells are shown in Fig. 8, 
which shows that the induction of γ-globin mRNA 
obtained with protocol C was, as expected, heterogene-
ous, yet with a trend comparable to that obtained using 
the two-phase protocol.
Fig. 4 a Erythroid differentiation (% of benzidine-positive, haemoglobin containing cells) evaluated at different days (as indicated) of the cell cul-
tures from different patients (each color represent one subject) (*P < 0.05). b, c HPLC analysis of the ErPCs cell cultures show representative examples 
of lysates containing moderate (b) and high (c) HbF endogenous levels. d Correlation between HbF levels determined using the two different cell 
culture protocols, the Fibach’s method (“Two-phases procedure”) and the protocol based on biobanked cells described in the present manuscript
Page 10 of 13Cosenza et al. J Transl Med  (2016) 14:255 
Fig. 5 a, b Representative chromatograms obtained from HPLC analysis carried out on thawed cells collected from the same patient at two dif-
ferent times. c–e Hemoglobin profile in ErPCs collected at two time points from three patients. c AVLTF; d AVLTA and e AVLTQ. f, g HPLC profiles of 
representative lysates obtained from one sampling; in this case two batches of cells were thawed at different times
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Discussion
Cellular biobanking is an important approach for col-
laborative networks planning to use same cells in 
studies aimed at solving different biological and bio-
medical issues [2, 23]. This is of key interest in studies on 
β-thalassemia, since the recruitment of patients and the 
needed blood drawing may present important limitations 
in the experimental planning. It should be noted that the 
commonly used approach is based on (a) recruitment of 
patients; (b) withdrawal of a 20–25  ml aliquot of blood 
before transfusion (please note that each patient usually 
has a personalized schedule for blood transfusion and 
therefore it is very difficult to treat in parallel erythroid 
precursor isolated from large numbers of patients); (c) 
culturing in vitro for a limited length of time; (d) use of 
cultures for determining the effects of HbF inducers as 
well as gene therapy approaches.
On the contrary, the use of biobanked samples allows 
simultaneous comparison of many potentially therapeu-
tic treatments on several samples growing in parallel.
The biobanked samples were validated for retention 
of the phenotype in relation to hemoglobin produc-
tion after thawing (a) frozen cells isolated from a same 
patient at different times (see Fig.  5a–e) and (b) differ-
ent frozen batches of a same patient’s cells (see Fig.  5f, 
g). This reproducibility was found in cultures of the same 
biobanked cells that were sent to different laboratories 
(see Fig. 7). The use of biobanked cells allows stratifica-
tion of the patients with respect to HbF production. 
Finally, the biobanked cells can be used for determining 
the response to pharmacological or other HbF inducers 
(Fig.  8). As far as characterization of other CFU-e and 
BFU-e markers, the data obtained so far are compatible 
with a BFU-e → CFUe progression during the differen-
tiation phase following thawing of cryopreserved cell and 
sub-culturing with SCF/EPO, characterized by decrease 
of CD29, CD44 and CD117 expression and increase of 
GPA. Further experiments are necessary to verify how 
Fig. 6 HbF and HbA2 production in ErPC cultures of 14 
β-thalassemia and SCA patients after 4 and 8 days differentiation. The 
hemoglobin levels were analyzed by HPLC and the percentage values 
obtained indicated. The upper panel shows the average ±SD of the 
samples presenting HbF >50 % and the lower panel shows the aver-
age of the samples with HbF <50 %, n number of ErPC samples
Fig. 7 Correlation between cell cultures from the cryopreserved vials 
from the same subject performed in different research laborato-
ries. HPLC analysis performed on 15 patients (β0-thalassemia and 
β+-thalassemia) in two different laboratories, at University of Ferrara 
(UniFE) and at the Cornell University in New York City (CU). Correlation 
between the % values of HbF (a) and HbA (b) evaluated in the cells 
cultured in the different laboratories
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the kinetics of these changes are related to other pub-
lished and validated cellular culture systems [20–22]. 
This characterization will be mandatory in the case other 
parameters (in addition to hemoglobin production and 
response to HbF inducers, which were the major objec-
tives of the present study) and will be considered for 
patient stratification and response to therapy. Transcrip-
tomics and proteomics data will be also very useful in 
this context.
The possibility to conduct pre-clinical testing on cells of 
a patient from the cellular Biobank represents an impor-
tant resource to study the response to novel HbF induc-
ers. In the future, if our system will be validated also for 
other erythroid-associated markers, in addition to the 
already analyzed CD117, CD44, CD29, GPA and CD71, 
this research activity will allow patients stratification tak-
ing into account all the phenotypic/genotypic character-
istics of individual ErPCs in association with in vitro HbF 
induction, under treatment with effective inducers.
Further, the cellular Biobank can provide a cell tem-
plate for the generation of induced pluripotent cells 
(iPS) for each patient [24, 25]. This is a great opportu-
nity, when considered together with the possibility of 
gene editing, which could lead to the correction of the 
genetic mutation by several approaches, including gene 
therapy and gene editing [26–31]. While up to now the 
cellular targets of gene therapy have been human eryth-
ropoietic stem cells in most studies, in the future we 
expect that induced pluripotent stem cells (iPSCs) from 
β-thalassemia patients will be also a useful cellular target 
of gene therapy and gene editing approaches [32]. The 
cryopreserved biobanked cells, therefore, might repre-
sents a very important biological source and resource for 
investigators, to perform exploratory experiments and 
generate preclinical data in these fields of investigation.
Conclusion
We demonstrated that freezing, cryopreservation and 
thawing steps maintain a steady erythroid differentia-
tion potential of the cells in terms of both kinetics and 
types of hemoglobin produced. The validation of the cel-
lular Thal-Biobank was consolidated by results obtained 
in other laboratories on different batches of the cryo-
preserved cells from the same patients. Also, these 
specimens provide an important opportunity for the 
research, to stratify patients based on all their pheno-
typic/genotypic characteristics, to evaluate the different 
ability of each individual to respond to inducers of HbF 
synthesis, and to develop novel therapeutic strategies for 
β-thalassemia.
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